Compare · ATNF vs JNJ
ATNF vs JNJ
Side-by-side comparison of 180 Life Sciences Corp. (ATNF) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATNF and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $558.86B, about 8578.3x ATNF ($65.1M).
- Over the past year, ATNF is up 587.9% and JNJ is up 49.6% - ATNF leads by 538.3 points.
- JNJ has hit the wire 8 times in the past 4 weeks while ATNF has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 1 for ATNF).
- Company
- 180 Life Sciences Corp.
- Johnson & Johnson
- Price
- $7.08-8.05%
- $232.15-0.24%
- Market cap
- $65.1M
- $558.86B
- 1M return
- +287.16%
- +4.36%
- 1Y return
- +587.86%
- +49.56%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 0
- 8
- Recent ratings
- 1
- 25
180 Life Sciences Corp.
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest ATNF
- SEC Form PRE 14A filed by 180 Life Sciences Corp.
- Chief Executive Officer Jordan Blair disposed of 200,000 shares (SEC Form 4)
- 180 Life Sciences Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- 180 Life Sciences Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 424B5 filed by 180 Life Sciences Corp.
- SEC Form S-3ASR filed by 180 Life Sciences Corp.
- SEC Form S-3ASR filed by 180 Life Sciences Corp.
- SEC Form S-3ASR filed by 180 Life Sciences Corp.
- 180 Life Sciences Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- Amendment: 180 Life Sciences Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Leadership Update, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Latest JNJ
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research